Immatics N.V. (IMTX) stock
IMTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$6.17−0.22 (-3.44%)
Close on Nov 16, 2026Market cap $827.22MP/E –Yield –
Immatics r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was €183.83M, up 24.1% from the year before. The highest annual figure on record is €183.83M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | €183.83M | +24.1% |
| FY2024 | Dec 31, 2024 | €148.08M | +24.8% |
| FY2023 | Dec 31, 2023 | €118.66M | +11.1% |
| FY2022 | Dec 31, 2022 | €106.78M | +21.9% |
| FY2021 | Dec 31, 2021 | €87.57M | +30.5% |
| FY2020 | Dec 31, 2020 | €67.09M | +67.3% |
| FY2019 | Dec 31, 2019 | €40.09M | +18.0% |
| FY2018 | Dec 31, 2018 | €33.97M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | €62.41M | +147.5% |
| Q2 FY2025 | Jun 30, 2025 | €45.11M | +121.8% |
| Q2 FY2024 | Jun 30, 2024 | €35.22M | +113.4% |
| Q2 FY2023 | Jun 30, 2023 | €27.32M | – |
| Q2 FY2022 | Jun 30, 2022 | €25.22M | – |
| Q2 FY2021 | Jun 30, 2021 | €20.34M | – |
| Q2 FY2020 | Jun 30, 2020 | €16.51M | – |
See a number that looks wrong?